[go: up one dir, main page]

PL2238982T3 - Środek do terapii mięsaka tkanek miękkich - Google Patents

Środek do terapii mięsaka tkanek miękkich

Info

Publication number
PL2238982T3
PL2238982T3 PL10162953T PL10162953T PL2238982T3 PL 2238982 T3 PL2238982 T3 PL 2238982T3 PL 10162953 T PL10162953 T PL 10162953T PL 10162953 T PL10162953 T PL 10162953T PL 2238982 T3 PL2238982 T3 PL 2238982T3
Authority
PL
Poland
Prior art keywords
compound
formula
therapeutic agent
soft tissue
tissue sarcoma
Prior art date
Application number
PL10162953T
Other languages
English (en)
Inventor
Tatsuo Ito
Toshifumi Ozaki
Mamoru Ouchida
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL2238982T3 publication Critical patent/PL2238982T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10162953T 2003-06-27 2004-06-25 Środek do terapii mięsaka tkanek miękkich PL2238982T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003183643 2003-06-27
EP10162953A EP2238982B8 (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma
EP04746840A EP1638541B1 (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma

Publications (1)

Publication Number Publication Date
PL2238982T3 true PL2238982T3 (pl) 2013-03-29

Family

ID=33549590

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10162953T PL2238982T3 (pl) 2003-06-27 2004-06-25 Środek do terapii mięsaka tkanek miękkich

Country Status (14)

Country Link
US (2) US7056883B2 (pl)
EP (2) EP2238982B8 (pl)
JP (1) JP4661782B2 (pl)
AT (1) ATE468113T1 (pl)
CA (1) CA2529840A1 (pl)
CY (1) CY1113534T1 (pl)
DE (1) DE602004027244D1 (pl)
DK (1) DK2238982T3 (pl)
ES (2) ES2341771T3 (pl)
MX (1) MXPA06000013A (pl)
PL (1) PL2238982T3 (pl)
PT (1) PT2238982E (pl)
SI (1) SI2238982T1 (pl)
WO (1) WO2005000332A2 (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
JP2005521737A (ja) * 2002-04-05 2005-07-21 藤沢薬品工業株式会社 腎臓癌の治療のためのデプシペプチド
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2519320A1 (en) * 2003-02-19 2004-09-02 Astellas Pharma Inc. Method of estimating antitumor effect of histone deacetylase inhibitor
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
ES2344899T3 (es) * 2003-09-25 2010-09-09 Astellas Pharma Inc. Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20060040575A1 (en) * 2004-08-18 2006-02-23 Kelleher Karen A Reflective printing on flame resistant fabrics
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1715334A1 (fr) * 2005-04-22 2006-10-25 Adamant Technologies SA Procédé utilisant un capteur électrochimique et électrodes formant ce capteur
NZ548087A (en) * 2005-04-29 2010-10-29 Tomizo Yamamoto Rubber or resin foam containing zirconium or germanium
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
ZA200800901B (en) 2005-07-14 2010-05-26 Takeda San Diego Inc Histone deacetylase inhibitors
EP1920779A4 (en) * 2005-08-12 2010-03-10 Astellas Pharma Inc YW753 PREPARATION STABILIZATION TECHNIQUE
WO2007024574A2 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
GB0518720D0 (en) * 2005-09-14 2005-10-19 Hamlet Pharma Ab Therapeutic combination
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer
WO2007056162A2 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
US20070117815A1 (en) * 2005-11-04 2007-05-24 James Pluda Method of treating cancers with SAHA and pemetrexed
AU2006318652A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the HDAC inhibitor FK228
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
EP2086323A4 (en) * 2006-11-03 2010-01-06 Univ Maryland METHOD OF USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
MX2009006969A (es) * 2006-12-29 2010-04-07 Gloucester Pharmaceuticals Purificacion de romidepsina.
JP2010516767A (ja) * 2007-01-23 2010-05-20 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンおよびｉ．ａ．ボルテゾミブを含む併用療法
UA114074C2 (xx) 2010-07-12 2017-04-25 Кристалічна форма с ромідепсину та її застосування для лікування шкірної т-клітинної лімфоми або периферичної т-клітинної лімфоми
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
MX2014008390A (es) * 2012-01-12 2014-09-22 Celgene Corp Formulaciones de romidepsina y sus usos.
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013331368A1 (en) 2012-10-15 2015-04-30 Epizyme, Inc. Methods of treating cancer
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
US9410943B2 (en) * 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
CA2921036A1 (en) * 2013-08-22 2015-02-26 Vanda Pharmaceuticals Inc. Use of trichostatin a in the treatment of cancer
WO2015058125A1 (en) * 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
EP3164154A1 (en) * 2014-07-03 2017-05-10 Imclone, LLC Combination therapy
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
JP2021512167A (ja) 2018-01-30 2021-05-13 フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 障害を治療するための方法及び化合物
WO2020160198A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2022523073A (ja) 2019-01-29 2022-04-21 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160196A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
US20220154282A1 (en) * 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
IL295101B1 (en) 2020-01-29 2025-10-01 Foghorn Therapeutics Inc Materials and their use
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60149520A (ja) * 1984-01-13 1985-08-07 Ajinomoto Co Inc 抗腫瘍剤
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5714164A (en) * 1991-02-28 1998-02-03 Parfums Christian Dior Method for treatment of allergic disorders and cosmetic compositions using cucurbitine
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
DE4137540A1 (de) * 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk Verwendung von praeparaten der curcuma-pflanzen
EP0654092B1 (en) * 1992-06-26 2003-09-10 The Trustees Of Princeton University Method for detecting pre-cancerous or cancerous cells using p90 and p53 antibodies or probes
US6124495A (en) * 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
IN188720B (pl) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
HK1042240B (en) * 1999-03-03 2004-05-07 Eurovita A/S Pharmaceuticals, dietary supplements and cosmetic compositions comprising a fatty acid and ginger
EP1438966B1 (en) 1999-12-08 2007-02-14 Cyclacel Pharmaceuticals, Inc. Use of depsipeptide and congeners thereof as immunosuppressants for treating an infectious disease, an autoimmune disease, allergic reactions or a hyperproliferative skin disease.
WO2002006307A1 (en) 2000-07-17 2002-01-24 Fujisawa Pharmaceutical Co., Ltd. Reduced fk228 and use thereof
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
AU2003226408B2 (en) 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
CA2433479A1 (en) * 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
CA2517346A1 (en) 2003-02-27 2004-09-10 Leonard A. Cohen Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors

Also Published As

Publication number Publication date
EP1638541A2 (en) 2006-03-29
EP2238982A3 (en) 2011-03-02
CY1113534T1 (el) 2016-06-22
EP2238982A2 (en) 2010-10-13
US20060223747A1 (en) 2006-10-05
WO2005000332A3 (en) 2005-03-24
US20050107290A1 (en) 2005-05-19
SI2238982T1 (sl) 2013-01-31
EP2238982B8 (en) 2013-01-16
ES2341771T3 (es) 2010-06-28
EP2238982B1 (en) 2012-10-17
PT2238982E (pt) 2013-01-22
EP1638541B1 (en) 2010-05-19
DK2238982T3 (da) 2013-01-28
JP4661782B2 (ja) 2011-03-30
ES2397079T3 (es) 2013-03-04
WO2005000332A2 (en) 2005-01-06
JP2007521259A (ja) 2007-08-02
US7056883B2 (en) 2006-06-06
CA2529840A1 (en) 2005-01-06
ATE468113T1 (de) 2010-06-15
MXPA06000013A (es) 2006-03-21
DE602004027244D1 (de) 2010-07-01

Similar Documents

Publication Publication Date Title
EP2238982B8 (en) Therapeutic agent for soft tissue sarcoma
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
DE60329001D1 (en) 8-hydroxychinolinderivate
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2008020027A3 (en) 2,5-dihydroxybenzene compounds for the treatment of skin cancer
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
TW200728307A (en) Novel spirochromanone derivatives
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
GEP20105134B (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
IL173062A0 (en) Substituted 2-aminotetralin for the treatment of depression
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
MX2007013624A (es) Inhibidores de proteina cinasa.
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
TW200639159A (en) Treatment of pain
EP2481429A3 (en) MMP Activated Vascular Disrupting Agents
WO2007047893A3 (en) Use of dasatinib for the treatment of bone metastasis
YU20902A (sh) Primena karbinola supstituisanih sa 2-imidazolilom za izradu medikamenta za lečenje ili profilaksu oboljenja izazvanih ishemičkim stanjima